HMG20B antibody (AA 31-50)

Catalog No. ABIN636227

Product Details anti-HMG20B Antibody

Target: HMG20B (High Mobility Group 20B (HMG20B))

Binding Specificity: AA 31-50

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HMG20B antibody is un-conjugated

Application: Western Blotting (WB)

Cross-Reactivity (Details): This antibodys immunogens shares 80 % sequence identity with its Mouse homolog.

Purification: Affinity chromatography purified

Immunogen: BRAF35 antibody was raised in rabbit using AA 31-50 [KQERGEGPRA GEKGSHEEEP] of the human structural DNA-binding protein BRAF35 as the immunogen.

Isotype: IgG

Application Details

Application Notes: WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Target Details for HMG20B

Target: HMG20B (High Mobility Group 20B (HMG20B))

Alternative Name: BRAF35 (HMG20B Products)

Synonyms: BRAF25 antibody, BRAF35 antibody, HMGX2 antibody, HMGXB2 antibody, PP7706 antibody, SMARCE1r antibody, SOXL antibody, pp8857 antibody, AW610687 antibody, Hmgx2 antibody, Hmgxb2 antibody, Smarce1r antibody, high mobility group 20 B antibody, high mobility group 20B antibody, Hmg20b antibody, HMG20B antibody

Background: Mutations of the human BRCA2 gene confer susceptibility to breast cancer. A structural DNA binding component has been identified and is designated as BRCA2-Associated Factor 35 (BRAF35). There is a close association of the BRAF35/BRCA2 complex with condensed chromatin coincident with histone H3 phosphorylation. Experimental evidence suggests a role for the BRCA2/BRAF35 complex in the modulation of cell cycle progression.